Compare Chevron Corp (CVX) vs Merck & Co., Inc. (MRK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs Merck & Co., Inc. — how do they compare? Chevron Corp trades at $179.31 (market cap $361.99B), while Merck & Co., Inc. trades at $123.5 (market cap $298.31B). The key difference: Chevron Corp is the larger of the two by market cap, and Chevron Corp pays the higher dividend (3.92%). Which is the better fit depends on your goals.
| CVX | MRK | |
|---|---|---|
Market Cap | $361.99B | $298.31B |
Volume | 9,807,834 | — |
Sector | Energy | Health |
52-Week High | $211.14 | $129.52 |
52-Week Low | $146.72 | $77.60 |
Enterprise Value | $402.09B | $341.72B |
Dividend Yield | 3.92% | 2.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $182.21, up 3.29% on the day, with bullish technical signals from moving averages and ADX indicators. Recent earnings have consistently beaten expectations, with Q1 2026 EPS of $1.41 surpassing the $1.00 estimate. The company maintains strong operating cash flow of $33.94 billion in 2025 and announced a $13.8 billion investment in Argentina's Vaca Muerta shale project, signaling growth commitment.
The outlook remains positive with a consensus price target of $207.56, implying 13.9% upside. High oil prices and strategic expansions support growth, but declining profit margins and geopolitical tensions pose risks. Analyst sentiment is strongly bullish with 62% buy ratings, though investors should monitor debt levels, which rose to 12.35% of assets in 2025.
Merck (MRK) trades at $123.45, down 0.47% on the day, with a bullish technical signal and strong analyst consensus. Recent earnings have consistently beaten expectations, including Q1 2026, and the company is actively expanding its oncology pipeline through acquisitions like Terns Pharmaceuticals. Revenue reached $65.01B in 2025 with a net income margin of 28.07%, though 2026 forecasts show a decline in profitability.
The outlook remains positive with a consensus price target of $137.30, offering ~11% upside. Key risks include increased debt levels, competitive pressures in oncology, and potential regulatory hurdles from acquisitions. Institutional buying activity supports confidence, but investors should monitor execution on growth initiatives and margin sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →
